News
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
Sonova further extends offering of Sennheiser-branded hearing solutions with All-Day Clear
Sonova further extends offering of Sennheiser-branded
hearing solutions with All-Day Clear
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2023:
Sonova shareholders approve all motions of the Board of Directors
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
Financial year 2022/23: Sonova delivers solid results and preserves profit growth
Financial year 2022/23: Sonova delivers solid results
and preserves profit growth
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory
Annual General Meeting of Kuros Biosciences approves all resolutions
Annual General Meeting of Kuros Biosciences approves all resolutions
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares